Cytomegalovirus Disease Clinical Trial
Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
Verified date | February 2023 |
Source | Nobelpharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective is to assess the efficacy and safety of NPC-21 when administered prophylactically to cytomegalovirus (CMV) seronegative patients receiving a first kidney transplant from a CMV seropositive donor.
Status | Completed |
Enrollment | 87 |
Est. completion date | February 8, 2023 |
Est. primary completion date | November 2, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 76 Years |
Eligibility | Inclusion Criteria: 1. Male or female patients 18 to 75 years of age in the United States or 20 to 75 years of age in Japan at the time of obtaining informed consent. 2. Patients must be CMV seronegative pre-transplant and scheduled to receive or have received (within 7 days prior to first study drug administration) a first kidney transplant from a CMV seropositive donor. 3. Patients must be willing and able to give written informed consent for participation in the study. 4. Patients must be eligible to undergo kidney transplantation from a living or deceased donor, as per institutional standards. 5. Patients must agree with contraception by using appropriate contraceptive measures. Exclusion Criteria: 1. Patients who have received a previous solid organ transplantation or hematopoietic stem cell transplantation. 2. Patients who receive a multi-organ transplant. 3. Patients who have CMV disease or CMV viremia at Screening. 4. Patients who have a positive donor-specific antibody within 90 days prior to Randomization confirmed via medical records. 5. Patients whose body weight is more than 120 kg at Screening. 6. Patients who have received the following anti-CMV therapy within 7 days prior to Randomization and/or plan to receive the following anti-CMV therapy during the study: ยท Anti-CMV agents (eg, foscarnet, ganciclovir, valganciclovir, letermovir, high dose acyclovir, high dose valacyclovir, high dose famciclovir, or cidofovir). Note: The use of anti-CMV agents per local standard of care during the Rescue Phase of the study is permitted. Note: The use of anti-herpes simplex virus and anti-varicella zoster virus prophylaxis for at-risk patients is recommended (as long as the doses are below the one specified above). 7. Patients who have received the following therapy within 28 days prior to Randomization and/or plan to receive the following anti-CMV therapy during the study: - CMV hyperimmune globulin (eg, CytoGam). - Intravenous immunoglobulin. - Plasmapheresis (receipt prior to first study drug administration is acceptable). 8. Patients with a history of a serious drug allergy to proteins, immunoglobulins, transfusions, or vaccines or any excipient of the NPC-21 formulation. 9. Patients with severe hepatic insufficiency at Screening (eg, Child-Pugh Class C). 10. Patients with active and untreated hepatitis B virus or hepatitis C virus, as documented as part of the pre-transplant screening. 11. Patients with known human immunodeficiency virus infection, based on medical records serology. 12. Patients with any uncontrolled infection at Randomization or a history of serious and uncontrolled infection within 6 months prior to Randomization. 13. Patients who are pregnant or lactating. 14. Patients with a history of malignancy within 5 years prior to Randomization other than curatively treated in situ cervical carcinoma, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma. 15. Patients with a history of alcohol or drug abuse or dependence within 1 year prior to Randomization that, in the opinion of the Investigator, would preclude study participation. 16. Patients who have previously participated in this study or any other study involving NPC-21. 17. Patients who have previously participated or are currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent. 18. Patients who have participated in another interventional clinical study and received another investigational product (ie, not approved by the Food and Drug Administration in the United States or the Ministry of Health, Labour and Welfare in Japan) within 90 days before Randomization. 19. Patients who are unable or unwilling, in the opinion of the Investigator, to comply with the protocol. |
Country | Name | City | State |
---|---|---|---|
Japan | Research site_213 | Hachioji-shi | Tokyo |
Japan | Marianna University School of Medicine | Kawasaki-shi | Kanagawa |
Japan | Research site_206 | Kobe | Hyogo |
Japan | Research site_212 | Kumamoto-shi | Kumamoto |
Japan | Research site_204 | Nagakute | Aichi |
Japan | Research site_201 | Nagoya | Aichi |
Japan | Research site_205 | Nishinomiya | Hyogo |
Japan | Osaka Metropolitan University Hospital | Osaka-shi | Osaka |
Japan | Research site_211 | Osaka-shi | Osaka |
Japan | Research site_214 | Osaka-shi | Osaka |
Japan | Research site_203 | Shimotsuke | Tochigi |
Japan | Research site_208 | Suita | Osaka |
Japan | Research site_215 | Tomigusuku-shi | Okinawa |
Japan | Research site_202 | Toyoake | Aichi |
United States | University of Michigan | Ann Arbor | Michigan |
United States | Piedmont Healthcare | Atlanta | Georgia |
United States | Augusta University Medical Center | Augusta | Georgia |
United States | The Christ Hospital | Cincinnati | Ohio |
United States | University of Cincinnati College of Medicine | Cincinnati | Ohio |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Renal Disease Research Institute | Dallas | Texas |
United States | University of Texas Southwestern | Dallas | Texas |
United States | California Institute of Renal Research | La Mesa | California |
United States | University of Wisconsin - Madison | Madison | Wisconsin |
United States | University of Minnesota | Minneapolis | Minnesota |
United States | University of Nebraska Medical Center | Omaha | Nebraska |
United States | Mayo Clinic - Scottsdale | Phoenix | Arizona |
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Nobelpharma |
United States, Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of CMV disease or CMV viremia | Percentage of patients with adjudicated CMV disease or CMV viremia through 16 weeks post-transplant | 16 weeks | |
Secondary | Incidence of CMV disease or CMV viremia | Percentage of patients with adjudicated CMV disease or CMV viremia. | 28 weeks | |
Secondary | Incidence of CMV disease | Percentage of patients with adjudicated CMV disease | 28 weeks | |
Secondary | Incidence of CMV viremia | Percentage of patients with adjudicated CMV viremia. | 28 weeks | |
Secondary | Time to detectable CMV disease or CMV viremia | 28 weeks | ||
Secondary | Time to detectable CMV disease | 28 weeks | ||
Secondary | Time to detectable CMV viremia | 28 weeks | ||
Secondary | Amount of CMV DNA | 28 weeks | ||
Secondary | Incidence and duration of anti-CMV therapy during the Rescue Phase | 28 weeks | ||
Secondary | Changes in EQ-5D-5L score from Baseline | 28 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02439970 -
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
|
Phase 3 | |
Terminated |
NCT02439957 -
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
|
Phase 3 | |
Active, not recruiting |
NCT04904614 -
Letermovir Use in Heart Transplant Recipients
|
Phase 4 | |
Completed |
NCT01509404 -
Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
|
Phase 4 | |
Completed |
NCT01573039 -
Cut Off for the Diagnosis of Cytomegalovirus (CMV) Disease in Serum-positive Kidney Transplant Recipients
|
N/A | |
Completed |
NCT00907686 -
TT-CMV Observational Birth Cohort Study
|
N/A | |
Completed |
NCT04129398 -
MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
|
Phase 3 | |
Recruiting |
NCT00828503 -
Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
|
Phase 2 |